Clinical Trial Evaluating the Effects of Ganaxolone in Children With Autism

NCT07635862 | Not Yet Recruiting Phase 2 DMC FDA Drug

• 1 other identifier: IRB-84478
• Study Type: interventional
• Target: 66
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to conduct a randomized, placebo-controlled trial (RCT) of ganaxolone, a neuroactive steroid (NAS), in autistic children and adolescents aged 5 to 17 years old. Ganaxolone is approved and effective for treating seizures in children as young as 2 years old who have CDKL5 deficiency disorder (CDD), a neurogenetic condition associated with developmental delays, seizure disorder, hypotonia, visual impairments, and autistic features. The primary outcome of interest for this trial is irritability on the Aberrant Behavior Checklist (ABC) because it is a common symptom of emotion dysregulation in ASD that impacts quality of life, including mental health, independence, educational opportunities, and integration into the community. The secondary domains of interest for this trial are restricted and repetitive behaviors (RRB), specifically insistence on sameness (IS), a subdomain of RRB characterized by inflexibility and a strong preference for predictable routines and familiar environments. Secondary outcome measures include the IS subscale from the Dimensional Assessment of Repetitive Behaviors (DARB) and subscales of the Clinical Global Impressions Scale for irritability (CGI-IR) and IS (CGI-IS). For participants living within 150 miles of Stanford University, we require participants to attend site visits and attempt EEG and MRI procedures before and after the trial, though we are recruiting nationally and the study can be completed without site vists.

Conditions

Autism Spectrum Disorder; Autism in Children; Autistic Disorder in Children and Adolescents

Keywords

Autism; Ganaxolone; Autism disorder in children and adolescents; Ztalmy; GABA; Insistance on Sameness; Emotional Regulation Difficulties; Irritability

Outcome Measures

Primary Outcomes (1)

• The score on irritability subscale on the Aberrant Behavior Checklist (ABC)

  It is a common symptom of emotion dysregulation in ASD that impacts quality of life, including mental health, independence, educational opportunities, and integration into the community, and ganaxolone may provide more direct benefits or increased tolerability compared to atypical antipsychotics.

  The measures will be completed at screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, and week 16.

Secondary Outcomes (3)

• The score of Insistence on Sameness subscale of the Dimensional Assessment of Repetitive Behaviors (DARB)

  The measures will be completed at screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, and week 16.

• The score on irritability subscale on the Clinical Global Impressions Scale (CGI-IR)

  The measures will be completed at screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, and week 16.

• The score on Insistence on Sameness subscale on the Clinical Global Impressions Scale(CGI-IS)

  These measures will be completed at screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12, week 14, and week 16.

Study Arms (2)

Ganaxolone Arm

ACTIVE COMPARATOR

Participants receives up to 20 weeks of Ganaxolone treatment

Drug: Ganaxolone (Ztalmy)

Placebo Arm

PLACEBO COMPARATOR

Participants receives up to 20 weeks of placebo treatment

Drug: Placebo

Interventions

Ganaxolone (Ztalmy) DRUG

Liquid oral suspension of ganaxolone will be administered orally with food three times daily. Dosage will be increased based on tolerability, no more frequently than every 7 days. Dosing will be flexible and occur between 4 to 8 weeks, depending on tolerability and response across each individual patient. Once the maximum tolerated dose is identified, it will be held stable for the remaining 4-8 weeks of the study, for a total of 12 weeks in the randomized, controlled phase. The titration schedule for patients weighing 28 kg or less is: Days 1-7: 2 mg/kg x 3 per day Days 8-14: 4 mg/kg x 3 per day Days 15-21: 8 mg/kg x 3 per day Days 22-28: 14 mg/kg x 3 per day Day 29 and thereafter: 21 mg/kg x 3 per day The titration schedule for patients weighing more than 28 kg is: Days 1-7: 50 mg/kg x 3 per day Days 8-14: 100 mg/kg x 3 per day Days 15-21: 200 mg/kg x 3 per day Days 22-28: 400 mg/kg x 3 per day Day 29 and thereafter: 600 mg/kg x 3 per day

Ganaxolone Arm

Placebo DRUG

The placebo suspension will contain the same components as the active compound, except for ganaxolone.

Placebo Arm

Eligibility Criteria

• Age: 5 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• children between the ages of 5 years and 17 years old at enrollment
• diagnosis of autism spectrum disorder based on DSM-5 criteria and confirmed with the Autism Diagnostic Inventory - Revised (ADI-R) and Autism Diagnostic Observation Schedule 2nd edition (ADOS-2), or Childhood Autism Rating Scales (CARS)
• medical stability based on clinical interview
• stable medication regimens (2 weeks, with the exception of fluoxetine for 4 weeks)
• stable psychosocial therapies (4 weeks) prior to randomization and no plans to change treatments or intensity during the trial
• high rates of irritability defined as the Aberrant Behavior Checklist irritability subscale score \> 18
• for participants who are sexually active, use of an effective contraceptive (e.g., birth control medications for female participants and condoms for male participants) and no plans for pregnancy throughout the trial
• for females, negative urine pregnancy test at baseline
• no planned changes in school placement
• for participants living within 150 miles of Stanford University, have the ability to attend site visits and attempt EEG and MRI procedures before and after the trial
• availability of a reliable informant who interacts with the participant regularly and can reliably complete assessments in English regarding their behaviors throughout the trial
• ability to participate in the testing administered in English to the extent that valid standard scores and biological samples can be obtained.

You may not qualify if:

• any unstable medical condition, such as unstable seizure disorder or heart disease
• any lifetime diagnosis of severe psychiatric (e.g., schizophrenia) or neurodegenerative conditions
• concomitant use of any neuroactive steroids or corticosteroids.
• history of substance abuse or active/planned use of alcohol, opioids, or cannabinoids
• recent history or current suicidal ideation assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS) and by clinical interview with the study physician
• pregnancy and mothers who are breastfeeding
• prior participation in any clinical trial in the 30 days prior to study entry
• known intolerance or hypersensitivity to ganaxolone or similar analogs
• Concomitant use of medications that are inducers of CYP450 3A4/5, such as rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's wort

Sponsors & Collaborators

• Stanford University: lead
• SPARK NS: collaborator

Study Sites (1)

Stanford University

Stanford, California, 94305, United States

Location

MeSH Terms

Conditions

Autistic Disorder; Autism Spectrum Disorder

Interventions

ganaxolone

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders

Study Officials

• Antonio Y. Hardan, M.D.

  Stanford University School of Medicine-Psychiatry and Behavioral Sciences - Child and Adolescent Psychiatry and Child Development

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Robin Libove, BS

CONTACT

(650) 736-1235; autismdd@stanford.edu

Briana Hernandez, BS

CONTACT

(650) 736-1235; autismdd@stanford.edu

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Psychiatry & Behavioral Sciences

Study Record Dates

• First Submitted: June 3, 2026
• First Posted: June 9, 2026
• Study Start (Estimated): January 1, 2027
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): January 1, 2030
• Last Updated: June 9, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)